News & Updates

Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical […]

The transaction includes the acquisition of Jeffs’ Brands’ wholly-owned subsidiary, Smart Repair Pro, and its approximately 49.1% ownership interest in SciSparc Nutraceutical Inc. by a Canadian public company in exchange for an up to 90% equity interest (on a fully diluted basis) in such company Tel Aviv, Israel, April 30, 2025 (GLOBE NEWSWIRE) -- Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, toda

The Vanguard S&P 500 ETF provides investors direct exposure to leading companies transforming AI, robotics, and transportation. With the Vanguard S&P 500 ETF (NYSEMKT: VOO) -- an exchange-traded fund (ETF) that tracks the performance of the benchmark S&P 500 -- down nearly 7% (at the time of this writing) in 2025 amid escalating trade tensions, many investors are questioning their core holdings.

Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical […]

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the deal terms, Novartis will pay $7 per share in cash upfront, or about $800 million, and another $7 per share to Regulus shareholders if the lead drug candidate, farabursen, gets regulatory approval, the California-based biotech said on Wednesday. The deal, expected to bolster Novartis' lineup of kidney disease drugs in development, will also give the company access to Regulus' proprietary platform to develop treatments targeting a type of genetic material called microRNAs.

Your day-ahead look for April 30, 2025

MARYSVILLE, Ohio (AP) — Scotts Miracle-Gro Co. (SMG) on Wednesday reported fiscal second-quarter earnings of $217.5 million. The Marysville, Ohio-based company said it had profit of $3.72 per share. Earnings, adjusted for non-recurring costs, were $3.98 per share.

Fueled by increased nearline cloud demand, STX's fiscal Q3 2025 top line grows 31% year over year. Enhanced margins positively impact the bottom line.

BROOKLYN, N.Y. (AP) — Etsy Inc. ETSY) on Wednesday reported a loss of $52.1 million in its first quarter. On a per-share basis, the Brooklyn, New York-based company said it had a loss of 49 cents.

Construction equipment maker Caterpillar on Wednesday reported a bigger first-quarter sales decline than analysts had forecast.